Based in Boston, Massachusetts and named after the Japanese deity that tamed fire for the good of humanity, Kojin is harnessing groundbreaking discoveries in cell-state and ferroptosis biology to develop first-in-class treatments for use in patients with cancer, and autoimmune and inflammatory diseases, among other disorders. Kojin has developed a drug-discovery platform that integrates computational chemistry, structural biology, chemical biology, target-informed screening, and mechanism-driven pharmacology to discover therapeutics that specifically modulate ferroptosis, a recently discovered and characterized cell-death mechanism. The Kojin team brings together scientific leadership in chemical biology, genetics, immunology, cancer therapeutics, drug discovery, and clinical development, as well as broad experience in biotechnology entrepreneurship.